HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maureen T Kelly Selected Research

oxidized low density lipoprotein

11/2012Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
4/2012One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
5/2011Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
2/2011Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
2/2011Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
10/2010Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
10/2010Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
1/2009Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Maureen T Kelly Research Topics

Disease

19Dyslipidemias (Dyslipidemia)
06/2014 - 12/2008
3Coronary Disease (Coronary Heart Disease)
06/2014 - 01/2008
2Type 2 Diabetes Mellitus (MODY)
02/2011 - 01/2010
2Hypertriglyceridemia
02/2011 - 01/2010
1Coronary Artery Disease (Coronary Atherosclerosis)
06/2014
1Chronic Renal Insufficiency
08/2013
1Cardiovascular Diseases (Cardiovascular Disease)
11/2012
1Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2010
1Hypercholesterolemia
01/2010
1Rhabdomyolysis
01/2010
1Myotoxicity
01/2010
1Headache (Headaches)
12/2008
1Nasopharyngitis
12/2008
1Respiratory Tract Infections (Respiratory Tract Infection)
12/2008
1Back Pain (Backache)
12/2008

Drug/Important Bio-Agent (IBA)

20fenofibric acidFDA Link
06/2014 - 12/2008
17LipidsIBA
08/2013 - 01/2008
12Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2014 - 12/2008
10Rosuvastatin Calcium (Crestor)FDA Link
08/2013 - 01/2009
9Triglycerides (Triacylglycerol)IBA
06/2014 - 01/2009
9LDL CholesterolIBA
06/2014 - 01/2009
8HDL CholesterolIBA
06/2014 - 01/2009
8oxidized low density lipoproteinIBA
11/2012 - 01/2009
4Atorvastatin (Lipitor)FDA Link
06/2014 - 02/2009
42- (4- (4- chlorobenzoyl)phenoxy)- 2- methylpropanoic acidIBA
05/2009 - 01/2009
3Fibric Acids (Fibrates)IBA
06/2014 - 01/2010
3Simvastatin (Zocor)FDA LinkGeneric
02/2011 - 01/2009
2Choline (Choline Chloride)IBA
06/2014 - 01/2009
2Lipoproteins (Lipoprotein)IBA
11/2012 - 05/2011
2Biomarkers (Surrogate Marker)IBA
09/2011 - 05/2011
2Apolipoproteins B (ApoB)IBA
05/2011 - 02/2011
2LDL Lipoproteins (beta Lipoproteins)IBA
03/2011 - 02/2009
2HDL LipoproteinsIBA
03/2011 - 02/2009
2ApolipoproteinsIBA
02/2011 - 01/2010
1Fenofibrate (CiL)FDA LinkGeneric
06/2014
1C-Reactive ProteinIBA
09/2011
1Ezetimibe (Zetia)FDA Link
10/2010
1SaltsIBA
01/2009

Therapy/Procedure

17Therapeutics
06/2014 - 12/2008
1Aftercare (After-Treatment)
02/2011